相关临床试验
375
106 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
11
2.9%
已完成
73
19.5%
Enrolling By Invitation
11
2.9%
尚未招募
84
22.4%
招募中
120
32.0%
暂停
1
0.3%
终止
1
0.3%
Unknown
73
19.5%
撤回
1
0.3%
暂无批准数据
- A heavily pretreated patient with relapsed/refractory diffuse large B-cell lymphoma achieved complete remission within 28 days following a single dose of Genocury Biotech's novel in vivo CD19 CAR-T therapy. - The groundbreaking treatment eliminated the need for lymphodepletion—a standard yet toxic preconditioning step in traditional CAR-T protocols—while demonstrating complete absence of cytokine release syndrome and neurotoxicity. - Genocury's proprietary technology delivers CAR payload directly into circulating T cells in vivo, potentially democratizing access to CAR-T therapy globally by reducing the $400,000 cost and 3-4 week timeline of traditional approaches.
- A phase II trial (INOVA) found that sintilimab combined with bevacizumab demonstrated activity in patients with relapsed or persistent ovarian clear cell carcinoma. - The combination therapy achieved an objective response rate of 40.5% and a disease control rate of 73% in evaluable patients. - Median progression-free survival was 6.9 months, and median overall survival reached 28.2 months with the sintilimab and bevacizumab regimen. - The treatment showed a manageable safety profile, with mostly grade 3 treatment-related adverse events and no grade 4 or 5 events reported.
